On January 8, 2020 Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, reported that Drew Fromkin, President and Chief Executive Officer, will present at the 2020 Biotech Showcase, occurring January 13-15, 2020 at the Hilton Union Square in San Francisco, CA (Press release, Tarveda Therapeutics, JAN 8, 2020, View Source [SID1234552869]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will take place at 9:45am Pacific Time on Tuesday, January 14 in Franciscan B (Ballroom Level).